Presymptom Health has raised funds in a seed financing round to advance the development of its blood test for the early identification of sepsis.
The funds, from Ploughshare Innovations and UK Innovation & Science Seed Fund, will allow the government spin-out medical technology company to conclude clinical trials at various hospitals in the UK as well as progress the diagnostic test towards approval and launch.
Go deeper with GlobalData
The test is based on findings from more than ten years of research at the Defence Science and Technology Laboratory (Dstl).
In preliminary trials, the test was able to predict sepsis onset in subjects up to three days prior to symptoms appearing, allowing doctors to treat the patients earlier and manage them more efficiently.
Currently, the trial, led by doctors from Portsmouth Hospitals University NHS Trust, is progressing at Portsmouth’s Queen Alexandra Hospital.
With the latest funding, a minimum of two more trial centres are expected to be activated this year, enrolling up to 600 subjects, Presymptom noted.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe present trials will continue for 12 to 18 months. Results will be independently evaluated and utilised to refine and establish the test.
The company plans to make the sepsis test available for wider National Health Service (NHS) usage in two years.
Presymptom Health CEO Iain Miller said: “We are delighted to have reached this crucial stage and grateful to Ploughshare Innovations and UK Innovation & Science Seed Fund for their invaluable support which will enable us to maximise the impact of the trial and validate our data.
“This funding is vital to our work in confirming our test’s ability to provide early diagnosis of a disease which affects up to 49 million patients annually and causes up to 11 million deaths each year around the globe.”
Sepsis is the overreaction of the body’s immune system to an infection or damage and is linked to fatal organ dysfunction.
